These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35157607)

  • 1. Antiplatelet Therapy in Acute Myocardial Infarction and Cardiogenic Shock: Insights From the National Cardiogenic Shock Initiative.
    Gorgis S; Lemor A; Kolski B; Lalonde T; Kaki A; Marso S; Senter S; Rahman A; Gorwara S; Nazir R; Zuberi O; Justice L; Srivastava N; Padgett R; O'Neill W; Basir MB
    J Invasive Cardiol; 2022 Mar; 34(3):E156-E163. PubMed ID: 35157607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
    Vogel RF; Delewi R; Angiolillo DJ; Wilschut JM; Lemmert ME; Diletti R; van Vliet R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Krucoff MW; van Mieghem NM; Smits PC; Vlachojannis GJ
    JACC Cardiovasc Interv; 2021 Jun; 14(12):1323-1333. PubMed ID: 34167672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Res; 2015 Jul; 136(1):87-93. PubMed ID: 25976448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
    De Backer O; Ratcovich H; Biasco L; Pedersen F; Helqvist S; Saunamäki K; Tilsted HH; Clemmensen P; Olivecrona G; Kelbaek H; Jørgensen E; Engstrøm T; Holmvang L
    Thromb Haemost; 2015 Aug; 114(3):623-31. PubMed ID: 25994355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
    Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Kukava NG; Pevsner DV; Rytova YK
    Kardiologiia; 2022 Sep; 62(9):44-53. PubMed ID: 36206137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
    Orban M; Kleeberger J; Ouarrak T; Freund A; Feistritzer HJ; Fuernau G; Geisler T; Huber K; Dudek D; Noc M; Montalescot G; Neumer A; Haller P; Clemmensen P; Zeymer U; Desch S; Massberg S; Schneider S; Thiele H; Hausleiter J
    Clin Res Cardiol; 2021 Sep; 110(9):1493-1503. PubMed ID: 33999281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newer P2Y
    Patlolla SH; Kandlakunta H; Kuchkuntla AR; West CP; Murad MH; Wang Z; Kochar A; Rab ST; Gersh BJ; Holmes DR; Zhao DX; Vallabhajosyula S
    Mayo Clin Proc; 2022 Jun; 97(6):1074-1085. PubMed ID: 35662424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
    Orban M; Limbourg T; Neumann FJ; Ferenc M; Olbrich HG; Richardt G; Hennersdorf M; Empen K; Fuernau G; Desch S; Eitel I; Hambrecht R; Pöss J; Schneider S; Schuler G; Werdan K; Zeymer U; Thiele H; Hausleiter J
    EuroIntervention; 2016 Dec; 12(11):e1395-e1403. PubMed ID: 26690314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
    Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre-treated with newer P2Y12 inhibitors.
    Blanchart K; Heudel T; Ardouin P; Lemaitre A; Briet C; Bignon M; Sabatier R; Legallois D; Roule V; Beygui F
    Clin Cardiol; 2021 Aug; 44(8):1080-1088. PubMed ID: 34114653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
    Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
    Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.